Optimising management of neutropenia and anaemia in cancer chemotherapy - Advances in cytokine therapy

Salvatore Siena, Simona Secondino, Laura Giannetta, Ornella Carminati, Paolo Pedrazzoli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Neutropenia and anaemia are serious complications of myelosuppressive chemotherapy. They have a negative impact on patient quality of life and may reduce response to treatment. Febrile neutropenia, a potentially life-threatening complication of neutropenia, frequently requires hospital admission, while fatigue and weakness from anaemia reduce patient's capacity for activity. Pegfilgrastim and darbepoetin alfa, were designed to simplify and optimise treatment for patients with cancer. Once-per-cycle pegfilgrastim is as effective as daily filgrastim with respect to duration of severe neutropenia (DSN) and may have a lower incidence of febrile neutropenia than filgrastim. Darbepoetin alfa has enhanced biological activity and a serum terminal half-life three-fold longer than that of erythropoietin (EPO), which translates into rapid and sustained correction of anaemia with less frequent dosing. These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
Volume48
Issue numberSUPPL.
DOIs
Publication statusPublished - Oct 15 2003

Fingerprint

Neutropenia
Anemia
Cytokines
Drug Therapy
Febrile Neutropenia
Neoplasms
Therapeutics
Erythropoietin
Fatigue
Half-Life
Quality of Life
Injections
Incidence
Serum
Filgrastim
Darbepoetin alfa
pegfilgrastim

Keywords

  • Anaemia
  • Cytokine
  • Darbepoetin alfa
  • Erythropoietin
  • Granulocyte colony-stimulating factor
  • Neutropenia
  • Pegfilgrastim

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Optimising management of neutropenia and anaemia in cancer chemotherapy - Advances in cytokine therapy. / Siena, Salvatore; Secondino, Simona; Giannetta, Laura; Carminati, Ornella; Pedrazzoli, Paolo.

In: Critical Reviews in Oncology/Hematology, Vol. 48, No. SUPPL., 15.10.2003.

Research output: Contribution to journalArticle

@article{e63f5b5298db429291300619cfdbfd02,
title = "Optimising management of neutropenia and anaemia in cancer chemotherapy - Advances in cytokine therapy",
abstract = "Neutropenia and anaemia are serious complications of myelosuppressive chemotherapy. They have a negative impact on patient quality of life and may reduce response to treatment. Febrile neutropenia, a potentially life-threatening complication of neutropenia, frequently requires hospital admission, while fatigue and weakness from anaemia reduce patient's capacity for activity. Pegfilgrastim and darbepoetin alfa, were designed to simplify and optimise treatment for patients with cancer. Once-per-cycle pegfilgrastim is as effective as daily filgrastim with respect to duration of severe neutropenia (DSN) and may have a lower incidence of febrile neutropenia than filgrastim. Darbepoetin alfa has enhanced biological activity and a serum terminal half-life three-fold longer than that of erythropoietin (EPO), which translates into rapid and sustained correction of anaemia with less frequent dosing. These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives.",
keywords = "Anaemia, Cytokine, Darbepoetin alfa, Erythropoietin, Granulocyte colony-stimulating factor, Neutropenia, Pegfilgrastim",
author = "Salvatore Siena and Simona Secondino and Laura Giannetta and Ornella Carminati and Paolo Pedrazzoli",
year = "2003",
month = "10",
day = "15",
doi = "10.1016/j.critrevonc.2003.05.002",
language = "English",
volume = "48",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

TY - JOUR

T1 - Optimising management of neutropenia and anaemia in cancer chemotherapy - Advances in cytokine therapy

AU - Siena, Salvatore

AU - Secondino, Simona

AU - Giannetta, Laura

AU - Carminati, Ornella

AU - Pedrazzoli, Paolo

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Neutropenia and anaemia are serious complications of myelosuppressive chemotherapy. They have a negative impact on patient quality of life and may reduce response to treatment. Febrile neutropenia, a potentially life-threatening complication of neutropenia, frequently requires hospital admission, while fatigue and weakness from anaemia reduce patient's capacity for activity. Pegfilgrastim and darbepoetin alfa, were designed to simplify and optimise treatment for patients with cancer. Once-per-cycle pegfilgrastim is as effective as daily filgrastim with respect to duration of severe neutropenia (DSN) and may have a lower incidence of febrile neutropenia than filgrastim. Darbepoetin alfa has enhanced biological activity and a serum terminal half-life three-fold longer than that of erythropoietin (EPO), which translates into rapid and sustained correction of anaemia with less frequent dosing. These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives.

AB - Neutropenia and anaemia are serious complications of myelosuppressive chemotherapy. They have a negative impact on patient quality of life and may reduce response to treatment. Febrile neutropenia, a potentially life-threatening complication of neutropenia, frequently requires hospital admission, while fatigue and weakness from anaemia reduce patient's capacity for activity. Pegfilgrastim and darbepoetin alfa, were designed to simplify and optimise treatment for patients with cancer. Once-per-cycle pegfilgrastim is as effective as daily filgrastim with respect to duration of severe neutropenia (DSN) and may have a lower incidence of febrile neutropenia than filgrastim. Darbepoetin alfa has enhanced biological activity and a serum terminal half-life three-fold longer than that of erythropoietin (EPO), which translates into rapid and sustained correction of anaemia with less frequent dosing. These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives.

KW - Anaemia

KW - Cytokine

KW - Darbepoetin alfa

KW - Erythropoietin

KW - Granulocyte colony-stimulating factor

KW - Neutropenia

KW - Pegfilgrastim

UR - http://www.scopus.com/inward/record.url?scp=0141918767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141918767&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2003.05.002

DO - 10.1016/j.critrevonc.2003.05.002

M3 - Article

C2 - 14563520

AN - SCOPUS:0141918767

VL - 48

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - SUPPL.

ER -